CN101817882B - Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4E4 monoclonal antibody - Google Patents
Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4E4 monoclonal antibody Download PDFInfo
- Publication number
- CN101817882B CN101817882B CN201010013661XA CN201010013661A CN101817882B CN 101817882 B CN101817882 B CN 101817882B CN 201010013661X A CN201010013661X A CN 201010013661XA CN 201010013661 A CN201010013661 A CN 201010013661A CN 101817882 B CN101817882 B CN 101817882B
- Authority
- CN
- China
- Prior art keywords
- epcam
- variable region
- fmu
- monoclonal antibody
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention discloses a light-chain variable region and a heavy-chain variable region of an FMU-EPCAM-4E4 monoclonal antibody, wherein an amino acid sequence of the light-chain variable region of the FMU-EPCAM-4E4 monoclonal antibody is shown as SEQ ID No.1, and an amino acid sequence of the heavy-chain variable region of the FMU-EPCAM-4E4 monoclonal antibody is shown as SEQ ID No.2. In the invention, a group of mouse anti-human EPCAM monoclonal antibodies is prepared by a recombinant human EPCAM immune BALB/c mouse, hybridoma cell strains which can stably secrete high-affinity anti-human EPCAM monoclonal antibodies are screened, and the high-affinity anti-human EPCAM monoclonal antibodies are obtained by preparing ascitic fluid. The invention confirms the uniqueness of a gene sequence and a corresponding protein sequence as well as a CDR sequence and provides support for anti-body EPCAM chimeric or humanized gene engineering antibodies.
Description
Technical field
The invention belongs to field of biomedicine technology, relate to a kind of monoclonal antibody, the light chain and the variable region of heavy chain of the FMU-EPCAM-4E4 monoclonal antibody of particularly a kind of anti-people EPCAM comprise its aminoacid sequence and nucleotide sequence.
Background technology
Epithelial cell adhesion molecule (EPCAM) is that the advantage epi-position as colorectal carcinoma is found at first, thinks that at that time its effect is cell adhesion and the treatment reliable connection site with antibody.Research at present thinks that EPCAM is glycosylated I type transmembrane glycoprotein, and molecular weight is 30 to 40kD, and its structure includes the after birth outskirt of an epidermal growth factor-like and a thyroglobulin sample, strides film district and one section 26 amino acid whose cytoplasmic domain for one section.EPCAM mainly is positioned at the tight junction in epithelial cell gap in normal cell.Intensity and the frequency expressed by EPCAM show, its basically high expression level in everyone adenocarcinoid, part squamous cell carcinoma, retinoblastoma and hepatocellular carcinoma.
Discovering the EPCAM function aspects: EPCAM has vital role before 2007 in cell proliferation, migration and signal transduction.For example: EPCAM expresses in the enhancing of people and rodent cell, has strengthened the propagation of cell grappling and the non-dependence of serum somatomedin and has increased as c-myc and cyclins in interior various target gene expression; At breast cancer cell line, the EPCAM signal is interfered through RNA, can cause the reduction of cell proliferation, migration and invasive ability.
Nearest studies confirm that: EPCAM can be used as one of surface marker of some noumenal tumour stem cells, also can be used as the integral part of normal stem cell surface marker.Simultaneously, result of study has also been explained the reason of EPCAM at the tumour cell high expression level well, and finds that itself and some tumour patient prognosis are relatively poor and survival rate is low relevant; And further explained the relation of EPCAM and tumour.In addition, mouse embryo stem cell experiment confirm, the EPCAM high expression level on tumor stem cell, normal stem cell and the rise of himself positive regeeration are to guaranteeing to keep these normal stem cells and extremely important with the propagation of pernicious stem cell.
The research that anti-EPCAM antibody is used for oncotherapy is the focus of Antybody therapy research always.As far back as the anti-EPCAM antibody of the mouse source property 17-1A of exploitation in 1979, just be used for clinical treatment to tumour in nineteen eighty-two.But mouse endogenous antibody medicine is when human body uses, because it has immunogenicity, can cause the immune response of human body, thereby cause the removing or the immunocomplex mediated hypersensitivity of antagonist medicine.Can partly solve its immunogenicity problem to the genetic modification of mouse endogenous antibody, as making up chimeric antibody or humanized antibody etc.
The antibody monomer molecule is by two identical heavy chains (H chain) and two identical light chains (L chain), the tetrapeptide chain structure that is formed by connecting by interchain disulfide bond.H chain and L chain comprise amino (N) end and carboxyl (C) end, are made up of hypervariable region/complementary determining region (HVR/CDR) and skeleton district (FR) near the variable region (V district) of N end; Be constant region (C district) near the C end.The protein folding that variable region of heavy chain (VH) and variable region of light chain (VL) form is an antigen-binding site, and CDR/HVR wherein is antibody and the complementary bonded of epitope position, and the reaction after the antigen-antibody identification is caused in the C district.Antibody can divide for people source, mouse source etc. according to FR/C district difference, the mouse endogenous antibody has immunogenicity when using in human body, easily cause the immune response of human body, these immune responses can cause the removing of mouse endogenous antibody and immunocomplex mediated hypersensitivity.In order to overcome the defective of mouse endogenous antibody, need to make up specific chimeric antibody, single-chain antibody or the humanized antibody of high-affinity.
In transformation process, of paramount importance is at first to obtain to have good specificity and avidity mouse source property parental antibody, clones its light chain and heavy chain variable region gene, then these two genes is transformed, and makes up the recombinant antibodies gene.At these problems, the research and development of anti-EPCAM therapeutic antibodies constantly make progress, the rat of anti-EPCAM and mouse bi-specific antibody Catumaxomab, single-chain antibody Proxinium, humanized antibody ING-1, the research that humanization fusion antibody EMD and full-length human antibody Adecatumumab priorities such as (MT201) enter clinical treatment tumour.In clinical trial, obtained good effect at present by the antibody A decatumumab treatment mammary cancer of transforming.Therefore, filter out the anti-people EPCAM of high-affinity mouse source property monoclonal antibody, therefrom clone light, heavy chain variable region gene, further improvement is the medication preparation of target spot with EPCAM and tumor treatment had very important significance.
Summary of the invention
The problem that the present invention solves is to provide the light chain and the variable region of heavy chain of the FMU-EPCAM-4E4 monoclonal antibody of a kind of anti-people EPCAM, comprise its amino acid and nucleotide sequence, chimeric or humanized genetic engineering antibody provides support for the anti-EPCAM that makes up high-affinity.
The present invention is achieved through the following technical solutions:
The light chain of FMU-EPCAM-4E4 monoclonal antibody and variable region of heavy chain, 3 complementary determining regions (CDR) sequence of described variable region of light chain is respectively:
CDR1：Gln-Ser-Leu-Leu-Asp-Ser-Asp-Gly-Lys-Thr-Tyr；
CDR2：Val-Val-Ser-Lys-Leu-Asp；
CDR3：Trp-Gln-Gly-Thr-His-Phe-Pro-Trp-Thr；
3 complementary determining regions (CDR) sequence of described variable region of heavy chain is respectively:
CDR1：Gly-Tyr-Ser-Phe-Tyr-Ser-Tyr-Trp；
CDR2：Ile-Tyr-Pro-Gly-Asn-Thr-Asp-Thr；
CDR3：Ile-Arg-Gly-Gly-Asn-Tyr。
The aminoacid sequence of described monoclonal antibody variable region of light chain such as SEQ ID NO.1, the aminoacid sequence of variable region of heavy chain is shown in SEQ ID NO.2.
The gene order of described coding monoclonal antibody variable region of light chain is shown in SEQ ID NO.3, and the gene order of encoding heavy chain variable region is shown in SEQ ID NO.4.
It is the preparation of the genetic engineering antibody or the diagnostic reagent of target spot that described monoclonal antibody is applied to people EPCAM.
Compared with prior art, the present invention has following beneficial technical effects:
1, the FMU-EPCAM-4E4 monoclonal antibody provided by the invention high-affinity monoclonal antibody that is a kind of anti-people EPCAM, through indirect ELISA detect, flow cytometer detects and confirms that this monoclonal antibody can be specifically in conjunction with people EPCAM;
2, clone this monoclonal antibody light chain, heavy chain variable region gene and aminoacid sequence, sequential analysis has confirmed the uniqueness of this antibody sequence.
3, analyze to obtain the CDR district of light chain, variable region of heavy chain, chimeric or humanized genetic engineering antibody provides support for the anti-people EPCAM of structure high-affinity on this basis.
Description of drawings
Fig. 1 is the FMU-EPCAM-4E4 monoclonal antibody of anti-people EPCAM and the EPCAM bonded flow cytometer detected result figure of COLO205 and SKBr-3 clone surface expression; Fig. 1 a combines detected result figure with COLO205 clone, and Fig. 1 b combines detected result figure with SKBr-3 clone; Wherein, FITC: fluorescein isothiocyanate, transverse axis are fluorescence intensity, and the longitudinal axis is relative cell counting, and M1 represents the positive cell scope;
Fig. 2 is the FMU-EPCAM-4E4 monoclonal antibody chain variable region gene homology sequence detected result figure of anti-people EPCAM;
Fig. 3 is the FMU-EPCAM-4E4 monoclonal antibody heavy chain variable region gene homology sequence detected result figure of anti-people EPCAM;
Fig. 4 is the FMU-EPCAM-4E4 monoclonal antibody variable region of light chain amino acid identity sequential detection figure as a result of anti-people EPCAM;
Fig. 5 is the FMU-EPCAM-4E4 monoclonal antibody variable region of heavy chain amino acid identity sequential detection figure as a result of anti-people EPCAM.
Embodiment
The applicant uses recombinant human EPCAM immunity BALB/c mouse, prepared one group of mouse anti human EPCAM monoclonal antibody, filter out the FMU-EPCAM-4E4 monoclonal antibody hybridoma cell strain of the anti-people EPCAM of energy stably excreting high-affinity, preparation ascites obtains the anti-people EPCAM of high-affinity monoclonal antibody.Confirm the uniqueness and the CDR sequence thereof of this gene order and corresponding protein sequence; Chimeric or humanized genetic engineering antibody provides support for anti-people EPCAM.
Below in conjunction with accompanying drawing the present invention is elaborated, the explanation of the invention is not limited.
The present invention specifically implements according to the following steps:
The preparation of 1 mouse anti human EPCAM high-affinity antibody
1.1 MONOCLONAL ANTIBODIES SPECIFIC FOR, purifying
With reference to GENBANK NM_002354 sequences Design primer, and the proteic gene of amplification coding people EPCAM after birth outskirt; Then this gene clone is gone in the pGEX-4T-3 carrier, make up prokaryotic expression carrier and transformed host cell; Induce by IPTG, freeze thawing adds the soluble protein that the ultrasonic degradation method obtains recombinant human EPCAM after birth outskirt again.
(cell and molecular immunology experimental technique first version P9-P17), are used recombinant human EPCAM after birth outskirt protein immunization BALB/c mouse (available from The Fourth Military Medical University's Experimental Animal Center) to press method for preparing monoclonal antibody; Initial immunity uses the Fu Shi Freund's complete adjuvant, and follow-up immunization uses freund 's incomplete adjuvant, each 3 weeks at interval, be subcutaneous multi-point injection, and immunity is 4 times altogether.Last immunity after 7-10 days blood sampling survey it and tire, detect immune effect.Behind the At intervals of two to three weeks,, put to death animal after 3 days and get spleen and carry out cytogamy through intravenous injection antigen booster immunization again.
The murine myeloma cell SP2/0 counting of taking the logarithm and growing prepares the immune spleen cell suspension simultaneously.Myeloma cell and splenocyte are carried out cytogamy by 1: 10 mixed.Merge the back cell suspension and add 96 orifice plates that contain feeder cell (normal Balb/c Turnover of Mouse Peritoneal Macrophages), 37 ℃, 5%CO
2Incubator is cultivated.After treating that the clone occurs, indirect ELISA detects, and selects positive colony.Adopt limiting dilution assay to carry out cloning to the cell that contains the positive colony hole, until obtain can stably excreting antibody hybridoma cell line (in-vitro cultivation was above 6 months), and its excretory antibody being carried out conventional caryogram is identified and Ig subclass mensuration, the result is the IgG2a subclass.
Obtain can the hybridoma cell strain of stably excreting antibody after, by mouse ascites preparation method preparation comprise monoclonal antibody ascites (cell and molecular immunology experimental technique first version, P9-P17).Ascites adopts QFF anion exchange chromatography purifying behind 40% saturated ammonium sulphate.With the purity of SDS-PAGE purification Identification antibody, the monoclonal antibody FMU-EPCAM-4E4 purity of purifying reaches 95%.
1.2 anti-people EPCAM monoclonal antibody titration
Relative affinity with monoclonal antibody (mAb) behind ascites and the purifying before the indirect ELISA method mensuration purifying.Wherein envelope antigen is the soluble protein of recombinant human EPCAM after birth outskirt, and testing sample is serial gradient dilution (1 * 10
1～10
9Gradient dilution) ascites and purifying after mAb, detecting antibody is sheep anti mouse-HRP enzymic-labelled antibody, substrate uses ABTS.The high-affinity FMU-EPCAM-4E4mAb that is filtered out, it is 1 * 10 that ascites is tired
-7, tiring behind the purifying is 0.6ng/ml, reaches 1 * 10 and generally adopt indirect ELISA detection ascites to tire
-5Above antibody can use.
1.3 the flow cytometry fluorescent dye detects anti-people EPCAM monoclonal antibody FMU-EPCAM-4E4 and cell surface EPCAM bonded activity
As negative antibody control, the EPCAM of Flow cytometry FMU-EPCAM-4E4mAb and COLO205 and SKBr-3 clone surface expression combines with SED mAb;
To logarithmic phase, adjusting cell concn is 5 * 10 with the 10%FCS-RPMI1640 culture medium culturing for COLO205 and SKBr-3 clone
6～1 * 10
7/ ml; Get 50 μ l cell suspensions and add specificity FMU-EPCAM-4E4mAb ascites 1 μ l, add 1 μ l deactivation normal rabbit serum again, hatch 30min for 4 ℃; Prepare negative control group with quadrat method.
Use washings (5%FCS-PBS-4%NaN then
3) cell of washing after hatching 2 times, add washings 2ml at every turn, abandon supernatant after 1000rpm * 5min is centrifugal; The sheep anti mouse fluorescent-labeled antibody that adds 100 μ l working concentrations, shake well is hatched 30min for 4 ℃;
With washings washing 2 times, each liquid feeding 2ml abandons supernatant after 1000rpm * 5min is centrifugal again; The streaming stationary liquid (2% glucose, 1% formaldehyde, the 0.02%NaN that add 0.5ml
3DPBS solution), carry out the situation that combines of flow cytometry FMU-EPCAM-4E4mAb and cell surface EPCAM then;
The result as shown in Figure 1, in COLO205 clone: compare with negative control, combine FMU-EPCAM-4E4mAb and the COLO205 cell that falls into M1 positive cell scope reaches 40%;
In SKBr-3 clone: compare with negative control, combine FMU-EPCAM-4E4mAb and the SKBr-3 cell that falls into M1 positive cell scope reaches 29%;
Above flow cytometry fluorescent dye detects and shows that FMU-EPCAM-4E4mAb can discern and in conjunction with the natural EPCAM of COLO205 and SKBr-3 cell surface expression.
By above-mentioned 2 kinds of FMU-EPCAM-4E4mAb in conjunction with experiment, qualification result at different levels shows, FMU-EPCAM-4E4mAb both can discern recombinant expressed EPCAM (indirect ELISA detection), again can recognizing cells the EPCAM of the natural expression in surface, illustrate that FMU-EPCAM-4E4mAb combines with corresponding antigens EPCAM and has good specificity and avidity.
The FMU-EPCAM-4E4 monoclonal antibody light chain of 2 anti-people EPCAM and the clone of heavy chain variable region gene
2.1FMU-EPCAM-4E4 the cultivation of hybridoma
(P88) FMU-EPCAM-4E4 hybridoma is cultivated based on 37 ℃ 5%CO with the RPMI 1640 that contains 10% calf serum for cell cultures, first version in recovery according to a conventional method
2Be cultured to logarithmic phase in the incubator.
2.2 the extraction of total RNA and cDNA first chain is synthetic
Adopt TRIZOL Reagent (available from U.S. GIBCO company) to extract total RNA, concrete operations step by specification carries out; The cDNA first chain synthetic agent box carries out reverse transcription synthetic cDNA first chain by product description available from U.S. GIBCO company after obtaining total RNA.
2.3PCR VL and the VH gene of method amplification FMU-EPCAM-4E4mAb
Pcr amplification reagent is available from TakaRa company, utilize VL F (upstream primer) and VL B (downstream primer) and VH F and two pairs of primers of VH B, with reverse transcription synthetic cDNA first chain is that template is carried out PCR, the VL of amplification FMU-EPCAM-4E4mAb and the VH gene of FMU-EPCAM-4E4mAb;
Reaction volume 50 μ l, reaction conditions is: 94 ℃ of 5min; 95 ℃ of 30s, 58 ℃ of 1min, 72 ℃ of 1min circulate 35 times; 72 ℃ of 7min; Primer sequence is:
VL?F：gttagatctc?cagcttggtc?cc 22bp；
VL?B：gacattcagc?tgacccagtc?tcca 24bp；
VH?F：tgaggagacg?gtgaccgtgg?tcccttggcc?ccag?34bp；
VH?B：aggtsmarct?gcagsagtcw?gg 22bp；
(the IUB standard annexs base code: s:c/g; M:a/c; R:a/g; W:a/t)
2.4PCR the clone of amplified production and screening
The PCR product is through 1.5% agarose gel electrophoresis; reclaim test kit (can take charge of) with a small amount of glue and reclaim pcr amplified fragment available from Shanghai China Shun biotechnology is limited; with dna ligation kit (available from TakaRa company) with this fragment by specification; utilization adds the A tail and inserts in the pMD-T18 carrier (available from TakaRa company); connector Transformed E .coli is (available from Chinese common micro-organisms DSMZ; CGMCC, Beijing), 37 ℃ of overnight incubation in Amp resistance LB agar culture dish.
Clone in the picking LB agar culture dish, 37 ℃ are shaken bacterium and spend the night in Amp resistance LB substratum, are template with 1 μ l bacterium liquid, by above-mentioned primer at light chain, variable region of heavy chain design, with the positive E.coli clone of PCR method screening reorganization;
Institute is obtained the positive E.coli clone of reorganization shake bacterium, thalline is delivered Shanghai biotechnology Services Co., Ltd and is finished gene sequencing, the gene order of variable region of light chain is shown in SEQ ID NO.3, and the gene order of variable region of heavy chain is shown in SEQ ID NO.4.
The nucleotide sequence of 3FMU-EPCAM-4E4mAb light chain and variable region of heavy chain and homology analysis
3.1 after determining that order-checking is errorless, in the GenBank+EMBL+DDBJ+PDB database, carry out nucleotide sequence homology analysis (Blastn).
The FMU-EPCAM-4E4mAb chain variable region gene is the highest with the mouse Ig chain variable region gene homology that is numbered GeneID:243420, reaches 281/289 (97%), as shown in Figure 2;
The FMU-EPCAM-4E4mAb heavy chain variable region gene is the highest with the mouse Ig heavy chain variable region gene homology that is numbered GeneID:668469, is 276/296 (93%), as shown in Figure 3.
Homology analysis shows, the nucleotide sequence of light, the variable region of heavy chain of coding FMU-EPCAM-4E4mAb, although certain homology is arranged with other gene order, do not find and the identical gene order of the present invention, show that the present invention has uniqueness on gene order.
3.2 variable region gene is translated into aminoacid sequence, carries out amino acid sequence analysis
The aminoacid sequence of monoclonal antibody variable region of light chain such as SEQ ID NO.1, the aminoacid sequence of variable region of heavy chain is shown in SEQ ID NO.2.
In non-redundant Genbank CDS translations+PDB+SwissProt+PIR+PRF Protein Data Bank, carry out amino acid sequence homology analysis (Blastp).
Analytical results shows that the FMU-EPCAM-4E4mAb light-chain amino acid sequence is the highest with the mouse Ig κ chain homology that is numbered ABR32168.1 GI:149799217, reaches 104/111 (93%), as shown in Figure 4;
The FMU-EPCAM-4E4mAb heavy chain amino acid sequence is the highest with the homology of the mouse Ig heavy chain protein that is numbered S55541GI:1363159, is 101/117 (86%), as shown in Figure 5.
Homology analysis shows, FMU-EPCAM-4E4mAb is light, the aminoacid sequence of variable region of heavy chain, although certain homology is arranged with other Argine Monohydrochloride sequence, do not find and the identical aminoacid sequence of the present invention, show that the present invention also has uniqueness on aminoacid sequence.
3.3 utilize IMGT/V-QUEST to analyze the variable region structure, determine the CDR district.
To check order gained FMU-EPCAM-4E4mAb light chain and weight chain variabl area sequence, (http://imgt.cines.fr/IMGT_vquest/vquest) analyzes in the IMGT/V-QUEST website, draws its CDR district.
3 complementary determining regions (CDR) sequence of variable region of light chain shown in SEQ ID NO.1 line part, is specially:
CDR1：Gln-Ser-Leu-Leu-Asp-Ser-Asp-Gly-Lys-Thr-Tyr；
CDR2：Val-Val-Ser-Lys-Leu-Asp；
CDR3：Trp-Gln-Gly-Thr-His-Phe-Pro-Trp-Thr；
3 complementary determining regions (CDR) sequence of described variable region of heavy chain is:
CDR1：Gly-Tyr-Ser-Phe-Tyr-Ser-Tyr-Trp；
CDR2：Ile-Tyr-Pro-Gly-Asn-Thr-Asp-Thr；
CDR3：Ile-Arg-Gly-Gly-Asn-Tyr。
4. genetic engineering antibody design
Based on expression, purifying and the sequential analysis of anti-people EPCAM monoclonal antibody FMU-EPCAM-4E4, the following biological products of design construction
1) structure of single-chain antibody: can FMU-EPCAM-4E4mAb of the present invention is light, heavy chain variable region gene connects by linker, insert protokaryon or carrier for expression of eukaryon, transform host bacterium or transfecting eukaryotic cells, being used for preparation can be to medicative single-chain antibodies of tumour such as mammary cancer, colorectal carcinoma and carcinoma of the pancreas.
2) structure of people-mouse-anti EPCAM chimeric antibody: can FMU-EPCAM-4E4mAb of the present invention is light, heavy chain variable region gene inserts in the universal chimeric antibody expression vector, acquisition contains the carrier transfecting eukaryotic cells of mosaic gene, is used for preparation and is expected medicative chimeric antibodies of tumour such as mammary cancer, colorectal carcinoma and carcinoma of the pancreas.
3) structure of humanized antibody: can be transplanted in the skeleton district (FR) of human antibody variable region in CDR district FMU-EPCAM-4E4mAb of the present invention is light, heavy chain variable region gene, form complementary determining region (CDR) grafted antibody (CDR-grafted antibody), also weigh structure antibody (reshapingantibody) or humanized antibody (humanized antibody).
Utilize CDR implantation technique engineered antibody, can obtain both to have kept mouse source property parent mAb specificity, again more near the novel antibody of people's antibody, being used for preparation can be to medicative humanized antibodies of tumour such as mammary cancer, colorectal carcinoma and carcinoma of the pancreas.
4) can be according to gene order of the present invention and amino acid sequence coded thereof, preparation is at other biological products of people EPCAM functional epitope.
5) can utilize the FMU-EPCAM-4E4 specific monoclonal antibody of anti-people EPCAM of the present invention as the instrument of distinguishing epithelium and non-epithelial origin tissue, to make a definite diagnosis the disease that some are easy to obscure.By adopting the FMU-EPCAM-4E4 specific monoclonal antibody dyeing of anti-people EPCAM of the present invention, the expression intensity of EPCAM in the tissues observed may be as the judgement symbol of some epithelial origin tumor prognosis and differentiation degree.
6) can use the proteic ELISA test kit of EPCAM after birth outskirt in the high-affinity FMU-EPCAM-4E4mAb formation determination body fluid of the present invention, be expected in the clinical diagnosis of tumour generation, development and prognosis, to be with a wide range of applications.
Amino acid and nucleotides sequence tabulation
＜110〉The Fourth Military Medical University of P.L.A
＜120〉light chain of FMU-EPCAM-4E4 monoclonal antibody and variable region of heavy chain
<160>4
<210>1
<211>111
<212>PRT
＜213〉synthetic
<400>1
Asp?Val?Val?Leu?Thr?Gln?Ser?Pro?Val?Thr?Leu?Ser?Val?Thr?Ile?Gly?Gln?Pro?Ala?Ser
1 5 10 15 20
Met?Ser?Cys?Lys?Ser?Ser?
Gln?Ser?Leu?Leu?Asp?Ser?Asp?Gly?Lys?Thr?Tyr?Leu?Asn?Trp
25 30 35 40
Leu?Leu?Gln?Arg?Pro?Gly?Gln?Ser?Pro?Lys?Arg?Leu?Ile?Tyr?
Val?Val?Ser?Lys?Leu?Asp
45 50 55 60
Pro?Gly?Val?Pro?Asp?Arg?Phe?Tyr?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Lys?Ile
65 70 75 80
Ser?Arg?Val?Glu?Ala?Glu?Asp?Leu?Gly?Val?Tyr?Tyr?Cys?
Trp?Gln?Gly?Thr?His?Phe?Pro
85 90 95 100
Trp?Thr?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Glu?Ile
105 110
<210>2
<211>113
<212>PRT
＜213〉synthetic
<400>2
Glu?Val?Gln?Leu?Gln?Glu?Ser?Gly?Thr?Val?Leu?Ala?Arg?Pro?Gly?Ala?Ser?Val?Lys?Met
1 5 10 15 20
Ser?Cys?Arg?Ala?Ser?
Gly?Tyr?Ser?Phe?Tyr?Ser?Tyr?Trp?Met?His?Trp?Leu?Lys?Gln?Arg
25 30 35 40
Pro?Gly?Gln?Gly?Leu?Glu?Trp?Ile?Gly?Gly?
Ile?Tyr?Pro?Gly?Asn?Thr?
Asp?Thr?Ser?Tyr
45 50 55 60
Asn?Pro?Lys?Phe?Lys?Asp?Lys?Ala?Lys?Leu?Thr?Ala?Val?Thr?Ser?Ala?Ser?Thr?Thr?Tyr
65 70 75 80
Met?Glu?Leu?Ser?Ser?Leu?Thr?Asp?Glu?Asp?Ser?Ala?Val?Tyr?Tyr?Cys?
Ile?Arg?Gly?Gly
85 90 95 100
Asn?Tyr?Trp?Gly?Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser
105 110
<210>3
<211>333
<212>DNA
＜213〉synthetic
<400>3
gatgttgtgc?tgacccagtc?tccagtcact?ttgtcggtta?ccattggaca?accagcctcc 60
atgtcttgca?agtcaagtca?gagcctctta?gatagtgatg?gaaagacata?tttgaattgg 120
ttgttgcaga?ggccaggcca?gtctccaaag?cgcctaatct?atgttgtgtc?taaattggac 180
cctggagtcc?ctgacaggtt?cactggcagt?ggatcaggga?cagatttcac?actgaaaatc 240
agcagagtgg?aggctgagga?tttgggagtt?tattattgct?ggcaaggtac?acattttccg 300
tggacgttcg?gtggagggac?caagctggag?atc 333
<210>4
<211>339
<212>DNA
＜213〉synthetic
<400>4
gaggtccagc?tgcaggagtc?tgggactgtg?ctggcaaggc?ctggggcttc?cgtgaagatg 60
tcctgcaggg?cttctggcta?cagctttacc?agctactgga?tgcactggct?aaaacagagg 120
cctggacagg?gtctagaatg?gattggtggt?atttatcctg?gaaatactga?tacaagctac 180
aacccgaagt?tcaaggacaa?ggccaaactg?actgcagtca?catccgccag?cactacctac 240
atggagctca?gcagcctgac?agatgaggac?tctgcggtct?attactgtat?aagagggggt 300
aactactggg?gccaagggac?cacggtcacc?gtctcctca 339
Claims (4)
1.FMU-EPCAM-4E4 monoclonal antibody comprises light chain and variable region of heavy chain, it is characterized in that, 3 complementary determining regions (CDR) sequence of the variable region of described light chain is:
CDR1：Gln-Ser-Leu-Leu-Asp-Ser-Asp-Gly-Lys-Thr-Tyr；
CDR2：Val-Val-Ser-Lys-Leu-Asp；
CDR3：Trp-Gln-Gly-Thr-His-Phe-Pro-Trp-Thr；
3 complementary determining regions (CDR) sequence of the variable region of described heavy chain is:
CDR1：Gly-Tyr-Ser-Phe-Tyr-Ser-Tyr-Trp；
CDR2：Ile-Tyr-Pro-Gly-Asn-Thr-Asp-Thr；
CDR3：Ile-Arg-Gly-Gly-Asn-Tyr。
2. FMU-EPCAM-4E4 monoclonal antibody as claimed in claim 1 is characterized in that, the aminoacid sequence of described monoclonal antibody variable region of light chain is shown in SEQ ID NO.1, and the aminoacid sequence of variable region of heavy chain is shown in SEQ ID NO.2.
3. FMU-EPCAM-4E4 monoclonal antibody as claimed in claim 1 is characterized in that, the gene order of coding monoclonal antibody variable region of light chain is shown in SEQ ID NO.3, and the gene order of encoding heavy chain variable region is shown in SEQ ID NO.4.
4. to be applied to people EPCAM be the preparation of the genetic engineering antibody or the diagnostic reagent of target spot for claim 1 or 3 described FMU-EPCAM-4E4 monoclonal antibodies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010013661XA CN101817882B (en) | 2010-01-22 | 2010-01-22 | Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4E4 monoclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010013661XA CN101817882B (en) | 2010-01-22 | 2010-01-22 | Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4E4 monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101817882A CN101817882A (en) | 2010-09-01 |
| CN101817882B true CN101817882B (en) | 2011-10-26 |
Family
ID=42653171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010013661XA Expired - Fee Related CN101817882B (en) | 2010-01-22 | 2010-01-22 | Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4E4 monoclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101817882B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110950959B (en) * | 2020-02-25 | 2020-07-03 | 和铂医药(上海)有限责任公司 | EpCAM-targeted antibody and preparation and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
-
2010
- 2010-01-22 CN CN201010013661XA patent/CN101817882B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101817882A (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11291720B2 (en) | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
| CN108779179B (en) | CD47 antibody, antigen binding fragment thereof and medical application thereof | |
| CN107151269B (en) | PDL-1 antibody, pharmaceutical composition and application thereof | |
| CN106977602B (en) | A kind of anti-PD1 monoclonal antibodies, its medical composition and its use | |
| CN101851291B (en) | Heavy chain and light chain variable regions of anti-human BAFF monoclonal antibody | |
| CN110520445B (en) | anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimer form bispecific antibody and preparation thereof | |
| CN101701039B (en) | Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies | |
| CN111744013B (en) | Methods and pharmaceutical combinations for treating diseases using anti-TIGIT antibodies in combination with PD-1 inhibitors | |
| WO2020098599A1 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
| CN112500485B (en) | anti-B7-H3 antibody and application thereof | |
| CN108712908A (en) | It is selfed len antibody | |
| CN109776678A (en) | A kind of humanization PD-L1 monoclonal antibody, preparation method and application | |
| CN112830969A (en) | Monoclonal antibody specifically binding to human Claudin18.2, and medicine and kit containing monoclonal antibody | |
| CN101440130A (en) | Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody | |
| CN113906053A (en) | anti-CEA antibodies and uses thereof | |
| JP2022516848A (en) | BTN3A binding protein and its use | |
| KR20230079165A (en) | Anti-Claudin18.2 and CD3 Bispecific Antibodies and Uses Thereof | |
| CN101899112B (en) | Light chain and heavy chain variable region of FMU-EPCAM-2D7 monoclonal antibody | |
| CN111944047B (en) | anti-BCMA humanized single-chain antibody and application thereof | |
| CN101817882B (en) | Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4E4 monoclonal antibody | |
| CN101817881B (en) | Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4F6 monoclonal antibody | |
| TW202309083A (en) | Anti-cldn4/anti-cd137 bispecific antibody | |
| CN117396515A (en) | anti-MSLN antibodies and uses thereof | |
| CN103265631B (en) | Heavy chain and light chain variable regions of anti-human CRT monoclonal antibody | |
| CN101585880B (en) | Variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111026 Termination date: 20210122 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |